Vaxfectin®, a cationic lipid-based adjuvant for protein-based influenza vaccines

被引:16
作者
Hartikka, Jukka [1 ]
Bozoukova, Vesselina [1 ]
Yang, Catherine K. [1 ]
Ye, Ming [1 ]
Rusalov, Denis [1 ]
Shlapobersky, Mark [1 ]
Vilalta, Adrian [1 ]
Wei, Qun [1 ]
Rolland, Alain [1 ]
Smith, Larry R. [1 ]
机构
[1] Vical Inc, San Diego, CA 92121 USA
关键词
Adjuvant; Cationic lipid; Vaccine; IMMUNE-RESPONSES; DENDRITIC CELLS; MICE; VIRUS; LIPOSOMES; ANTIBODY; HEMAGGLUTININ; PROTECTION; CHALLENGE; INDUCTION;
D O I
10.1016/j.vaccine.2009.06.014
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Mice were immunized either with unadjuvanted seasonal trivalent influenza vaccine (TIV) or TIV formulated with Vaxfectin (R), a cationic lipid-based adjuvant. Increasing doses of Vaxfectin (R) resulted in increased hemagglutination-inhibition or anti-TIV ELISA antibody titers, with up to a 200-fold increase obtained with 900 mu g of Vaxfectin (R). A >= 10-fold dose-sparing effect was demonstrated with Vaxfectin (R) formulations. Vaxfectin (R) preferentially increased IgG2 titers compared to IgG1 titers, resulting in a balanced IgG isotype distribution. Lower doses of Vaxfectin (R) (30 mu g) did not enhance antibody responses, but increased the number of IFN-gamma secreting T-cells by up to 18-fold. The data demonstrate that Vaxfectin (R) enhances Th1 responses with protein-based seasonal influenza vaccine, and suggest that cellular or humoral immune responses may be preferentially induced by modifying the Vaxfectin (R):antigen ratio in the vaccine formulation. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6399 / 6403
页数:5
相关论文
共 24 条
  • [1] Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection
    Bungener, Laura
    Geeraedts, Felix
    Ter Veer, Wouter
    Medema, Jeroen
    Wilschut, Jan
    Huckriede, Anke
    [J]. VACCINE, 2008, 26 (19) : 2350 - 2359
  • [2] Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype
    Feng, JQ
    Mozdzanowska, K
    Gerhard, W
    [J]. JOURNAL OF VIROLOGY, 2002, 76 (03) : 1369 - 1378
  • [3] Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition
    Foged, C
    Arigita, C
    Sundblad, A
    Jiskoot, W
    Storm, G
    Frokjaer, S
    [J]. VACCINE, 2004, 22 (15-16) : 1903 - 1913
  • [4] Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine
    Guy, B
    Pascal, N
    Françon, A
    Bonnin, A
    Gimenez, S
    Lafay-Vialon, E
    Trannoy, E
    Haensler, J
    [J]. VACCINE, 2001, 19 (13-14) : 1794 - 1805
  • [5] Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens
    Hartikka, J
    Bozoukova, V
    Ferrari, M
    Sukhu, L
    Enas, J
    Sawdey, M
    Wloch, MK
    Tonsky, K
    Norman, J
    Manthorpe, M
    Wheeler, CJ
    [J]. VACCINE, 2001, 19 (15-16) : 1911 - 1923
  • [6] Physical characterization and in vivo evaluation of poloxamer-based DNA vaccine formulations
    Hartikka, Jukka
    Geall, Andrew
    Bozoukova, Vesselina
    Kurniadi, David
    Rusalov, Denis
    Enas, Joel
    Yi, Ji-Hyun
    Nanci, Antonio
    Rolland, Alain
    [J]. JOURNAL OF GENE MEDICINE, 2008, 10 (07) : 770 - 782
  • [7] A cationic lipid-formulated plasmid DNA vaccine confers sustained anti body-mediated protection against aerosolized anthrax spores
    Hermanson, G
    Whitlow, V
    Parker, S
    Tonsky, K
    Rusalov, D
    Ferrari, M
    Lalor, P
    Komai, M
    Mere, R
    Bell, M
    Brenneman, K
    Mateczun, A
    Evans, T
    Kaslow, D
    Galloway, D
    Hobart, P
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (37) : 13601 - 13606
  • [8] Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza
    Huber, Victor C.
    McKeon, Raelene M.
    Brackin, Martha N.
    Miller, Laura A.
    Keating, Rachael
    Brown, Scott A.
    Makarova, Natalia
    Perez, Daniel R.
    MacDonald, Gene H.
    McCullers, Jonathan A.
    [J]. CLINICAL AND VACCINE IMMUNOLOGY, 2006, 13 (09) : 981 - 990
  • [9] Vaxfectin™-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge
    Jimenez, Gretchen S.
    Planchon, Rodrick
    Wei, Qun
    Rusalov, Denis
    Geall, Andrew
    Enas, Joel
    Lalor, Peggy
    Leamy, Vicky
    Vahle, Ruth
    Luke, Catherine J.
    Rolland, Alain
    Kaslow, David C.
    Smith, Larry R.
    [J]. HUMAN VACCINES, 2007, 3 (05): : 157 - 164
  • [10] A new intranasal influenza vaccine based on a novel polycationic lipid - ceramide carbamoyl-spermine (CCS) - I. Immunogenicity and efficacy studies in mice
    Joseph, Aviva
    Itskovitz-Cooper, Noga
    Samira, Sarit
    Flasterstein, Orli
    Eliyahu, Hagit
    Simberg, Dmitri
    Goldwaser, Itzik
    Barenholz, Yechezkel
    Kedar, Eli
    [J]. VACCINE, 2006, 24 (18) : 3990 - 4006